A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC)

被引：8

作者：

Dieras, V.

Jassem, J.

Dirix, L. Y.

Guastalla, J. P.

Bono, P.

Hurvitz, S. A.

Goncalves, A.

Romieu, G.

Limentani, S. A.

Jerusalem, G. H. M.

Lakshmaiah, K.

Roche, H. H.

Sanchez-Rovira, P.

Pienkowski, T.

Segui-Palmer, M. A.

Li, A.

Sun, Y.

Pickett-Gies, C. A.

Wildiers, H.

机构：

[1] Inst Curie, Dept Med Oncol, Paris, France

[2] Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland

[3] Sint Augustinus, Antwerp, Belgium

[4] Ctr Leon Berard, Lyon, France

[5] Helsinki Univ Hosp, Helsinki, Finland

[6] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[7] Inst Paoli Calmettes, Marseille, France

[8] CRLC Val DAurelle, Montpellier, France

[9] Carolinas Hematol Oncol Associates, Charlotte, NC USA

[10] CHU Sart Tilman, B-4000 Liege, Belgium

[11] Kidwai Mem Inst Oncol, Bangalore, Karnataka, India

[12] Inst Claudius Regaud, Toulouse, France

[13] Complejo Hosp Jaen, Jaen, Spain

[14] Klin Nowotworow, Ctr Oncol, Warsaw, Poland

[15] Corp Sanitaria Parc Taull, Sabadell, Spain

[16] Amgen Inc, Dept Biostat & Epidemiol, Thousand Oaks, CA 91320 USA

[17] Amgen Inc, Dept Pharmacokinet & Drug Metab, Thousand Oaks, CA 91320 USA

[18] Amgen Inc, Oncol Clin Dev, Thousand Oaks, CA 91320 USA

[19] Multidisciplinary Breast Ctr, Dept Gen Med Oncol, Leuven, Belgium

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期

关键词：

D O I：

10.1200/jco.2011.29.15_suppl.544

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

544

引用

页数：1